• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

There Is Now Compelling Evidence to Further Evaluate Lower Doses of Abiraterone Acetate in Men With Metastatic Prostate Cancer: It Should Be Safer, May Be as Effective and Less Expensive.

作者信息

Velho Pedro Isaacsson, Eisenberger Mario A

机构信息

Pedro Isaacsson Velho and Mario A. Eisenberger, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.

出版信息

J Clin Oncol. 2018 Oct 20;36(30):3059-3060. doi: 10.1200/JCO.2018.79.3166. Epub 2018 Sep 6.

DOI:10.1200/JCO.2018.79.3166
PMID:30188787
Abstract
摘要

相似文献

1
There Is Now Compelling Evidence to Further Evaluate Lower Doses of Abiraterone Acetate in Men With Metastatic Prostate Cancer: It Should Be Safer, May Be as Effective and Less Expensive.现有令人信服的证据表明，应进一步评估低剂量醋酸阿比特龙用于转移性前列腺癌男性患者的情况：它可能更安全，或许同样有效且成本更低。
J Clin Oncol. 2018 Oct 20;36(30):3059-3060. doi: 10.1200/JCO.2018.79.3166. Epub 2018 Sep 6.
2
A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.一项关于日本转移性去势抵抗性前列腺癌患者中醋酸阿比特龙序贯多西他赛治疗的多中心回顾性分析。
Jpn J Clin Oncol. 2015 Aug;45(8):774-9. doi: 10.1093/jjco/hyv070. Epub 2015 May 15.
3
Defining End Points in Phase II Trials of Metastatic Castration-Resistant Prostate Cancer. Re: Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study.转移性去势抵抗性前列腺癌II期试验中的终点定义。回复：在接受阿比特龙治疗期间疾病进展的转移性去势抵抗性前列腺癌患者中添加二甲双胍至阿比特龙的影响（MetAb-Pro）：2期试点研究。
Clin Genitourin Cancer. 2019 Oct;17(5):e886-e887. doi: 10.1016/j.clgc.2019.07.010. Epub 2019 Jul 19.
4
Author's Reply to Srinivas: "Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer".作者对斯里尼瓦斯的回复：“转移性去势抵抗性前列腺癌患者中阿比特龙暴露与前列腺特异性抗原动态关系的建模”
Clin Pharmacokinet. 2017 Feb;56(2):213-214. doi: 10.1007/s40262-016-0469-1.
5
Re: Prostate-Specific Antigen Decline after 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer.回复：醋酸阿比特龙治疗4周后前列腺特异性抗原下降情况及转移性去势抵抗性前列腺癌患者的总生存期
J Urol. 2016 Jul;196(1):103. doi: 10.1016/j.juro.2016.04.040. Epub 2016 Apr 14.
6
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.醋酸阿比特龙治疗化疗后进展的转移性去势抵抗性前列腺癌患者：多中心、开放标签、早期准入方案试验的最终分析。
Lancet Oncol. 2014 Oct;15(11):1263-8. doi: 10.1016/S1470-2045(14)70417-6. Epub 2014 Sep 18.
7
Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.回复：帕斯夸莱·雷西格诺、大卫·洛伦特、迪莱塔·比安基尼等。醋酸阿比特龙治疗4周后前列腺特异性抗原下降情况及转移性去势抵抗性前列腺癌患者的总生存期。《欧洲泌尿外科杂志》2016年；70卷：724 - 31页
Eur Urol. 2016 Dec;70(6):e168-e169. doi: 10.1016/j.eururo.2016.05.028. Epub 2016 May 30.
8
Dose Reduction May Jeopardize Efficacy of Abiraterone Acetate.剂量降低可能危及醋酸阿比特龙的疗效。
J Clin Oncol. 2018 Oct 20;36(30):3062-3064. doi: 10.1200/JCO.2018.79.3182. Epub 2018 Sep 6.
9
Comment on: "Modeling the Relationship between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer".关于《转移性去势抵抗性前列腺癌患者阿比特龙暴露与前列腺特异性抗原动力学之间的关系建模》的评论
Clin Pharmacokinet. 2017 Feb;56(2):211-212. doi: 10.1007/s40262-016-0468-2.
10
Early use of abiraterone and radium-223 in metastatic prostate cancer.阿比特龙和镭-223在转移性前列腺癌中的早期应用。
Lancet Oncol. 2019 May;20(5):e229. doi: 10.1016/S1470-2045(19)30235-9.

引用本文的文献

1
The REthinking Clinical Trials Program Retreat 2023: Creating Partnerships to Optimize Quality Cancer Care.2023 年重新思考临床试验计划务虚会：建立合作关系以优化癌症护理质量。
Curr Oncol. 2024 Mar 6;31(3):1376-1388. doi: 10.3390/curroncol31030104.
2
Dose optimization during drug development: whether and when to optimize.药物开发过程中的剂量优化：是否以及何时进行优化。
J Natl Cancer Inst. 2023 May 8;115(5):492-497. doi: 10.1093/jnci/djac232.
3
Fucoidan Independently Enhances Activity in Human Immune Cells and Has a Cytostatic Effect on Prostate Cancer Cells in the Presence of Nivolumab.
岩藻聚糖硫酸酯可独立增强人免疫细胞的活性，并在使用纳武利尤单抗的情况下对前列腺癌细胞产生细胞生长抑制作用。
Mar Drugs. 2021 Dec 22;20(1):12. doi: 10.3390/md20010012.